Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $622,000.

  • Mereo BioPharma Group's Other Accumulated Expenses fell 76.48% to $622,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $622,000, marking a year-over-year decrease of 76.48%. This contributed to the annual value of $1.1 million for FY2024, which is 7.25% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Other Accumulated Expenses of $622,000 as of Q3 2025, which was down 19.95% from $777,000 recorded in Q2 2025.
  • Mereo BioPharma Group's Other Accumulated Expenses' 5-year high stood at $3.4 million during Q2 2024, with a 5-year trough of $40,298 in Q2 2022.
  • Over the past 3 years, Mereo BioPharma Group's median Other Accumulated Expenses value was $957,500 (recorded in 2023), while the average stood at $1.4 million.
  • Over the last 5 years, Mereo BioPharma Group's Other Accumulated Expenses had its largest YoY gain of 24.51% in 2025, and its largest YoY loss of 77.38% in 2025.
  • Mereo BioPharma Group's Other Accumulated Expenses (Quarterly) stood at $123,000 in 2021, then crashed by 67.24% to $1.1 million in 2022, then declined by 4.67% to $1.0 million in 2023, then climbed by 7.25% to $1.1 million in 2024, then tumbled by 76.48% to $622,000 in 2025.
  • Its last three reported values are $622,000 in Q3 2025, $777,000 for Q2 2025, and $894,000 during Q1 2025.